Pulmonary Fibrosis Biomarker Market
Description
Pulmonary Fibrosis Biomarker: Global Industry Analysis 2019-2023 and Opportunity Assessment 2024-2034
A recent market study published by FMI on Pulmonary Fibrosis Biomarker offers a global industry analysis for 2019-2023 and opportunity assessment for 2024-2034. The study offers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historical and current growth parameters, the growth prospects of the market are obtained with maximum precision.
Market Segmentation
By Test:
Executive Summary
The executive summary of the Pulmonary Fibrosis Biomarker includes the global market outlook, demand side trends, supply side trends and also include FMI analysis and recommendations of Pulmonary Fibrosis Biomarker.
Chapter 01 - Market Overview
Readers can find the detailed segmentation and definition of the Pulmonary Fibrosis Biomarker in this chapter, which will help to understand basic information about Pulmonary Fibrosis Biomarker. This section also highlights the market scope, taxonomy and limitations which help the reader understand the market coverage of Pulmonary Fibrosis Biomarker report.
Chapter 02 - Market Background
This chapter includes detailed analysis of the By Test processing methods overview, consumer buying patterns & tendencies and policy developments and regulatory scenario. It also includes in depth analysis of macro-economic factors and covers topics like global GDP growth outlook, global industry value added, personal consumption, expenditures, modern trade penetration and consumer price indices. The chapter also covers forecast factors - relevance & impact, value chain analysis and market dynamics (drivers, restraints and opportunities) to better understand the market.
Chapter 03 - Global Pulmonary Fibrosis Biomarker Demand Analysis 2019-2023 and Forecast, 2024-2034
The chapter include historical market value (XX) analysis (2019-2023) and current and future market value (USD 6,538.4 million) and volume (4.4%) projections (2024-2034). The projections are based on the Y-O-Y growth trend analysis and absolute $ opportunity analysis country of operation.
Chapter 04 - Global Pulmonary Fibrosis Biomarker - Pricing Analysis
Based on By Test, the pricing analysis chapter include Regional pricing analysis (USD/MT), global average pricing analysis benchmark, and key factors impacting the pricing.
Chapter 05 - Global Pulmonary Fibrosis Biomarker Analysis 2019-2023 and Forecast 2024-2034, By Test
Based on By Test, Pulmonary Fibrosis Biomarker is segmented into Blood Tests, Imaging Tests, Lung Biopsy. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Test.
Chapter 06 - Global Pulmonary Fibrosis Biomarker Analysis 2019-2023 and Forecast 2024-2034, By Indication
Based on By Indication, Pulmonary Fibrosis Biomarker is segmented into Idiopathic pulmonary fibrosis (IPF), Rheumatoid Arthritis Interstitial Lung Disease (RA-ILD), Drug-induced pulmonary fibrosis, COVID-19-related pulmonary fibrosis, Pneumoconiosis, Sarcoidosis, Others. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Indication.
Chapter 07 - Global Pulmonary Fibrosis Biomarker Analysis 2019-2023 and Forecast 2024-2034, By End User
Based on By End User, Pulmonary Fibrosis Biomarker is segmented into Hospitals, Specialty Clinics, Diagnostic Laboratories, Diagnostic Imaging Centers. This section also offers market attractiveness analysis based on By End User. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By End User.
Chapter 08 - Pulmonary Fibrosis Biomarker Analysis 2019-2023 and Forecast 2024-2034, By Region
Based on By Region, Pulmonary Fibrosis Biomarker is segmented into North America, Latin America, Europe, East Asia, South Asia, Oceania and Middle East & Africa. This section also offers market attractiveness analysis based on By Region. Readers can also find value forecast and Y-o-Y growth comparison for all above mentioned By Region.
Chapter 09 - North America Pulmonary Fibrosis Biomarker Analysis 2019-2023 and Forecast 2024-2034
This chapter includes a detailed analysis of the growth of the Pulmonary Fibrosis Biomarker in the North American region, along with a country-wise assessment that includes the US and Canada. Readers can also find regional trends, regulations, and market growth based on different segment and countries in the North America region.
Chapter 10 - Latin America Pulmonary Fibrosis Biomarker Analysis 2019-2023 and Forecast 2024-2034
This chapter includes a detailed analysis of the growth of Pulmonary Fibrosis Biomarker in the Latin America region, along with a country-wise assessment that includes the Brazil, Mexico, Chile, Argentina, Peru and Rest of Latin America. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Pulmonary Fibrosis Biomarker in the Latin America region.
Chapter 11 - Europe Pulmonary Fibrosis Biomarker Analysis 2019-2023 and Forecast 2024-2034
This chapter includes a detailed analysis of the growth of Pulmonary Fibrosis Biomarker in the European region, along with a country-wise assessment that includes the Germany, Italy, France, U.K., Spain, Russia, Nordic, Benelux and Rest of Europe. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Pulmonary Fibrosis Biomarker in the regional market.
Chapter 12 - East Asia Pulmonary Fibrosis Biomarker Analysis 2019-2023 and Forecast 2024-2034
This chapter includes a detailed analysis of the growth of Pulmonary Fibrosis Biomarker in the East Asia region, along with a country-wise assessment that includes the China, Japan, and South Korea. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Pulmonary Fibrosis Biomarker in the regional market.
Chapter 13 - South Asia Pulmonary Fibrosis Biomarker Analysis 2019-2023 and Forecast 2024-2034
This chapter includes a detailed analysis of the growth of Pulmonary Fibrosis Biomarker in the South Asia region, along with a country-wise assessment that includes the India, Indonesia, Malaysia, Thailand, and Rest of South Asia. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Pulmonary Fibrosis Biomarker in the regional market.
Chapter 14 - Middle East and Africa Pulmonary Fibrosis Biomarker Analysis 2019-2023 and Forecast 2024-2034
This chapter includes a detailed analysis of the growth of Pulmonary Fibrosis Biomarker in the MEA region, along with a country-wise assessment that includes the GCC Countries, South Africa, North Africa, Turkey and Rest of MEA. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Pulmonary Fibrosis Biomarker in the regional market.
Chapter 15 - Key Countries Pulmonary Fibrosis Biomarker Analysis 2019-2023 and Forecast 2024-2034
This chapter offers insights into how the Pulmonary Fibrosis Biomarker is expected to grow in major countries globally.
Chapter 16 - Market Structure Analysis- Global Assessment
This chapter includes company dashboard, industry structure analysis by tier of companies, 2022E, company share analysis of top players, 2022E, and competition benchmarking- matrix.
Chapter 17 - Competition Deep Dive (Tentative List)
This chapter includes company overview, By Test portfolio of companies, profitability by market segments, sales footprint, SWOT analysis and strategy overview of the companies being studied in the report. Some of the market players featured in the report are Biogen, Veracyte, Genentech (Roche), Galapagos NV, Biocartis, Myriad Genetics
Chapter 18 - Assumptions and Acronyms
This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the Pulmonary Fibrosis Biomarker report.
Chapter 19 - Research Methodology
This chapter helps readers understand the research methodology followed to obtain various conclusions, as well as important qualitative and quantitative information, on Pulmonary Fibrosis Biomarker.
A recent market study published by FMI on Pulmonary Fibrosis Biomarker offers a global industry analysis for 2019-2023 and opportunity assessment for 2024-2034. The study offers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historical and current growth parameters, the growth prospects of the market are obtained with maximum precision.
Market Segmentation
By Test:
- Blood Tests
- Imaging Tests
- Lung Biopsy
- Idiopathic pulmonary fibrosis (IPF)
- Rheumatoid Arthritis Interstitial Lung Disease (RA-ILD)
- Drug-induced pulmonary fibrosis
- COVID-19-related pulmonary fibrosis
- Pneumoconiosis
- Sarcoidosis
- Others
- Hospitals
- Specialty Clinics
- Diagnostic Laboratories
- Diagnostic Imaging Centers
- North America
- Latin America
- East Asia
- South Asia and Pacific
- Western Europe
- Eastern Europe
- Middle East Asia
Executive Summary
The executive summary of the Pulmonary Fibrosis Biomarker includes the global market outlook, demand side trends, supply side trends and also include FMI analysis and recommendations of Pulmonary Fibrosis Biomarker.
Chapter 01 - Market Overview
Readers can find the detailed segmentation and definition of the Pulmonary Fibrosis Biomarker in this chapter, which will help to understand basic information about Pulmonary Fibrosis Biomarker. This section also highlights the market scope, taxonomy and limitations which help the reader understand the market coverage of Pulmonary Fibrosis Biomarker report.
Chapter 02 - Market Background
This chapter includes detailed analysis of the By Test processing methods overview, consumer buying patterns & tendencies and policy developments and regulatory scenario. It also includes in depth analysis of macro-economic factors and covers topics like global GDP growth outlook, global industry value added, personal consumption, expenditures, modern trade penetration and consumer price indices. The chapter also covers forecast factors - relevance & impact, value chain analysis and market dynamics (drivers, restraints and opportunities) to better understand the market.
Chapter 03 - Global Pulmonary Fibrosis Biomarker Demand Analysis 2019-2023 and Forecast, 2024-2034
The chapter include historical market value (XX) analysis (2019-2023) and current and future market value (USD 6,538.4 million) and volume (4.4%) projections (2024-2034). The projections are based on the Y-O-Y growth trend analysis and absolute $ opportunity analysis country of operation.
Chapter 04 - Global Pulmonary Fibrosis Biomarker - Pricing Analysis
Based on By Test, the pricing analysis chapter include Regional pricing analysis (USD/MT), global average pricing analysis benchmark, and key factors impacting the pricing.
Chapter 05 - Global Pulmonary Fibrosis Biomarker Analysis 2019-2023 and Forecast 2024-2034, By Test
Based on By Test, Pulmonary Fibrosis Biomarker is segmented into Blood Tests, Imaging Tests, Lung Biopsy. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Test.
Chapter 06 - Global Pulmonary Fibrosis Biomarker Analysis 2019-2023 and Forecast 2024-2034, By Indication
Based on By Indication, Pulmonary Fibrosis Biomarker is segmented into Idiopathic pulmonary fibrosis (IPF), Rheumatoid Arthritis Interstitial Lung Disease (RA-ILD), Drug-induced pulmonary fibrosis, COVID-19-related pulmonary fibrosis, Pneumoconiosis, Sarcoidosis, Others. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Indication.
Chapter 07 - Global Pulmonary Fibrosis Biomarker Analysis 2019-2023 and Forecast 2024-2034, By End User
Based on By End User, Pulmonary Fibrosis Biomarker is segmented into Hospitals, Specialty Clinics, Diagnostic Laboratories, Diagnostic Imaging Centers. This section also offers market attractiveness analysis based on By End User. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By End User.
Chapter 08 - Pulmonary Fibrosis Biomarker Analysis 2019-2023 and Forecast 2024-2034, By Region
Based on By Region, Pulmonary Fibrosis Biomarker is segmented into North America, Latin America, Europe, East Asia, South Asia, Oceania and Middle East & Africa. This section also offers market attractiveness analysis based on By Region. Readers can also find value forecast and Y-o-Y growth comparison for all above mentioned By Region.
Chapter 09 - North America Pulmonary Fibrosis Biomarker Analysis 2019-2023 and Forecast 2024-2034
This chapter includes a detailed analysis of the growth of the Pulmonary Fibrosis Biomarker in the North American region, along with a country-wise assessment that includes the US and Canada. Readers can also find regional trends, regulations, and market growth based on different segment and countries in the North America region.
Chapter 10 - Latin America Pulmonary Fibrosis Biomarker Analysis 2019-2023 and Forecast 2024-2034
This chapter includes a detailed analysis of the growth of Pulmonary Fibrosis Biomarker in the Latin America region, along with a country-wise assessment that includes the Brazil, Mexico, Chile, Argentina, Peru and Rest of Latin America. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Pulmonary Fibrosis Biomarker in the Latin America region.
Chapter 11 - Europe Pulmonary Fibrosis Biomarker Analysis 2019-2023 and Forecast 2024-2034
This chapter includes a detailed analysis of the growth of Pulmonary Fibrosis Biomarker in the European region, along with a country-wise assessment that includes the Germany, Italy, France, U.K., Spain, Russia, Nordic, Benelux and Rest of Europe. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Pulmonary Fibrosis Biomarker in the regional market.
Chapter 12 - East Asia Pulmonary Fibrosis Biomarker Analysis 2019-2023 and Forecast 2024-2034
This chapter includes a detailed analysis of the growth of Pulmonary Fibrosis Biomarker in the East Asia region, along with a country-wise assessment that includes the China, Japan, and South Korea. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Pulmonary Fibrosis Biomarker in the regional market.
Chapter 13 - South Asia Pulmonary Fibrosis Biomarker Analysis 2019-2023 and Forecast 2024-2034
This chapter includes a detailed analysis of the growth of Pulmonary Fibrosis Biomarker in the South Asia region, along with a country-wise assessment that includes the India, Indonesia, Malaysia, Thailand, and Rest of South Asia. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Pulmonary Fibrosis Biomarker in the regional market.
Chapter 14 - Middle East and Africa Pulmonary Fibrosis Biomarker Analysis 2019-2023 and Forecast 2024-2034
This chapter includes a detailed analysis of the growth of Pulmonary Fibrosis Biomarker in the MEA region, along with a country-wise assessment that includes the GCC Countries, South Africa, North Africa, Turkey and Rest of MEA. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Pulmonary Fibrosis Biomarker in the regional market.
Chapter 15 - Key Countries Pulmonary Fibrosis Biomarker Analysis 2019-2023 and Forecast 2024-2034
This chapter offers insights into how the Pulmonary Fibrosis Biomarker is expected to grow in major countries globally.
Chapter 16 - Market Structure Analysis- Global Assessment
This chapter includes company dashboard, industry structure analysis by tier of companies, 2022E, company share analysis of top players, 2022E, and competition benchmarking- matrix.
Chapter 17 - Competition Deep Dive (Tentative List)
This chapter includes company overview, By Test portfolio of companies, profitability by market segments, sales footprint, SWOT analysis and strategy overview of the companies being studied in the report. Some of the market players featured in the report are Biogen, Veracyte, Genentech (Roche), Galapagos NV, Biocartis, Myriad Genetics
Chapter 18 - Assumptions and Acronyms
This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the Pulmonary Fibrosis Biomarker report.
Chapter 19 - Research Methodology
This chapter helps readers understand the research methodology followed to obtain various conclusions, as well as important qualitative and quantitative information, on Pulmonary Fibrosis Biomarker.
Table of Contents
311 Pages
- 1. Executive Summary
- 2. Market Overview
- 3. Key Market Trends
- 4. Value Added Insights
- 5. Market Background
- 6. Global Market Demand (in Value or Size in USD Million) Analysis 2018 to 2023 and Forecast, 2024 to 2034
- 7. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Test Type
- 7.1. Blood Tests:
- 7.1.1. C-Reactive Protein Testing Kits
- 7.1.2. Antibody Testing Kits
- 7.1.2.1. Antinuclear Antibodies (ANA) Test
- 7.1.2.2. Anti-CCP antibody testing
- 7.1.3. ESR Tests and CBC
- 7.2. Imaging Tests
- 7.2.1. X-rays Scans
- 7.2.2. HRCT Scans
- 7.3. Lung Biopsy
- 8. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Indication
- 8.1. Idiopathic Pulmonary Fibrosis (IPF)
- 8.2. Rheumatoid Arthritis Interstitial Lung Disease (RA-ILD)
- 8.3. Drug-induced Pulmonary Fibrosis
- 8.4. COVID-19-related Pulmonary Fibrosis
- 8.5. Pneumoconiosis
- 8.6. Sarcoidosis
- 8.7. Others
- 9. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User
- 9.1. Hospitals
- 9.2. Specialty Clinics
- 9.3. Diagnostic Laboratories
- 9.4. Diagnostic Imaging Centers
- 10. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Region
- 10.1. North America
- 10.2. Latin America
- 10.3. East Asia
- 10.4. South Asia and Pacific
- 10.5. Western Europe
- 10.6. Eastern Europe
- 10.7. Middle East and Africa
- 11. North America Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 12. Latin America Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 13. East Asia Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 14. South Asia and Pacific Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 15. Western Europe Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 16. Eastern Europe Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 17. Middle East and Africa Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 18. Market Structure Analysis
- 19. Competition Analysis
- 19.1. Roche Diagnostics
- 19.2. Siemens Healthineers
- 19.3. Bio-Rad Laboratories
- 19.4. Eagle Biosciences, Inc.
- 19.5. Biogenix Inc. Pvt. Ltd.
- 19.6. Diagnostic Automation/Cortez Diagnostics Inc.
- 19.7. BioSupply Ltd.
- 19.8. Bio-Diagnostics Ltd.
- 19.9. MERIDIAN BIOSCIENCE
- 19.10. Weldon Biotech, Inc.
- 19.11. Getein Biotech, Inc.
- 19.12. Creative Diagnostics
- 19.13. Beijing Strong Biotechnologies, Inc.
- 19.14. Merck KGaA
- 19.15. CTK Biotech, Inc.
- 19.16. Personal Diagnostics
- 19.17. Thermo Fisher Scientific Inc.
- 20. Assumptions and Acronyms Used
- 21. Research Methodology
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
